Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Sponsor
University of Alberta
Study ID
NCT07272837
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Study Details

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

Key Dates

First listed
Dec 9, 2025
Start date
May 15, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2027
Completion
Apr 30, 2028

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Changes in skeletal and cardiac muscle mass [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Obesity / overweight trialsType 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies